New once-daily HIV drug helps with patient compliance

Article

Emtriva is the first once-daily nucleoside reverse transcriptase inhibitor to receive a nod of approval from the FDA.

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

© 2025 MJH Life Sciences

All rights reserved.